Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication after severe asthma. The anti-TSLP antibody has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback